Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

25.59 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RBAZ Bancorp, Inc. (OTCPK - RBAZ), Squarespace, Inc. (NYSE - SQSP), PlayAGS, Incorporated (NYSE - AGS), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH)

June 18, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

June 03, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

May 30, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

May 20, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Squarespace, Inc. (NYSE – SQSP), PlayAGS, Incorporated (NYSE – AGS), HashiCorp Inc. (Nasdaq – HCP), Deciphera Pharmaceuticals, Inc. (Nasdaq – DCPH)

May 13, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: PlayAGS, Incorporated (NYSE - AGS), HashiCorp Inc. (Nasdaq - HCP), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH), Territorial Bancorp, Inc. (Nasdaq - TBNK)

May 09, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH

May 01, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HashiCorp Inc. (Nasdaq - HCP), Heartland Financial, USA Inc. (Nasdaq - HTLF), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH), Territorial Bancorp, Inc. (Nasdaq -

April 29, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders

April 29, 2024

From Halper Sadeh LLC

Via Business Wire

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion

April 29, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum

April 09, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

February 27, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results

February 06, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024

February 01, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 01, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

January 18, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company

January 08, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

January 05, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

November 29, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

November 07, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results

October 30, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT

October 30, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 15, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results

August 09, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

August 03, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023

August 02, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

May 25, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

May 23, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.